Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2008 2
2010 2
2011 3
2012 3
2013 9
2014 8
2015 7
2016 11
2017 16
2018 27
2019 19
2020 10
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 33214159

100 results
Results by year
Filters applied: . Clear all
Page 1
Are SGLT2 Inhibitors Safe and Effective in Advanced Diabetic Kidney Disease?
Zoungas S, Polkinghorne KR. Zoungas S, et al. Clin J Am Soc Nephrol. 2020 Nov 19:CJN.16351020. doi: 10.2215/CJN.16351020. Online ahead of print. Clin J Am Soc Nephrol. 2020. PMID: 33214159 No abstract available.
SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
Alicic RZ, Johnson EJ, Tuttle KR. Alicic RZ, et al. Am J Kidney Dis. 2018 Aug;72(2):267-277. doi: 10.1053/j.ajkd.2018.03.022. Epub 2018 Jun 14. Am J Kidney Dis. 2018. PMID: 29866460 Review.
The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
Jaikumkao K, Pongchaidecha A, Chatsudthipong V, Chattipakorn SC, Chattipakorn N, Lungkaphin A. Jaikumkao K, et al. Biomed Pharmacother. 2017 Oct;94:176-187. doi: 10.1016/j.biopha.2017.07.095. Epub 2017 Jul 29. Biomed Pharmacother. 2017. PMID: 28759755 Review.
Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
Thomson SC, Vallon V. Thomson SC, et al. Am J Cardiol. 2019 Dec 15;124 Suppl 1(Suppl 1):S28-S35. doi: 10.1016/j.amjcard.2019.10.027. Am J Cardiol. 2019. PMID: 31741437 Review.
The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.
Fattah H, Vallon V. Fattah H, et al. Drugs. 2018 May;78(7):717-726. doi: 10.1007/s40265-018-0901-y. Drugs. 2018. PMID: 29663292 Free PMC article. Review.
SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. Fioretto P, et al. Diabetes Care. 2016 Aug;39 Suppl 2:S165-71. doi: 10.2337/dcS15-3006. Diabetes Care. 2016. PMID: 27440829
SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients.
Vasquez-Rios G, Nadkarni GN. Vasquez-Rios G, et al. Int J Nephrol Renovasc Dis. 2020 Oct 28;13:281-296. doi: 10.2147/IJNRD.S268811. eCollection 2020. Int J Nephrol Renovasc Dis. 2020. PMID: 33149657 Free PMC article. Review.
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
Liu B, Wang Y, Zhang Y, Yan B. Liu B, et al. Curr Top Med Chem. 2019;19(20):1818-1849. doi: 10.2174/1568026619666190828161409. Curr Top Med Chem. 2019. PMID: 31456521 Review.
Development of SGLT1 and SGLT2 inhibitors.
Rieg T, Vallon V. Rieg T, et al. Diabetologia. 2018 Oct;61(10):2079-2086. doi: 10.1007/s00125-018-4654-7. Epub 2018 Aug 22. Diabetologia. 2018. PMID: 30132033 Free PMC article. Review.
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Lo C, et al. Cochrane Database Syst Rev. 2018 Sep 24;9(9):CD011798. doi: 10.1002/14651858.CD011798.pub2. Cochrane Database Syst Rev. 2018. PMID: 30246878 Free PMC article. Review.
100 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback